Iridex (IRIX) AI Stock Analysis

Compare

127 Followers

IRIX Dividends

Top Page

Iridex

(NASDAQ:IRIX)

48Neutral

Iridex's overall stock score reflects significant financial difficulties, with declining revenues and negative margins. However, recent strategic initiatives, including cost reductions and a strategic investment, provide a glimmer of hope for future stability and growth. The technical analysis suggests a cautious market sentiment, while the valuation is challenging due to the negative earnings. Overall, the company appears to be at a critical juncture, requiring successful execution of its strategic actions to improve its financial health.

Iridex (IRIX) vs. S&P 500 (SPY)

Market Cap

$20.48M

Dividend YieldN/A

Average Volume (3M)124.61K

Price to Earnings (P/E)―

Beta (1Y)0.42

Revenue Growth-6.17%

EPS Growth8.27%

CountryUS

Employees93

SectorHealthcare

Sector Strength69

IndustryMedical - Devices

Share Statistics

EPS (TTM)-0.54

Shares Outstanding16,789,026

10 Day Avg. Volume61,110

30 Day Avg. Volume124,607

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.34

Price to Cash Flow (P/CF)-1.30

P/FCF Ratio0.00

Enterprise Value/Market Cap1.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.54

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Iridex Business Overview & Revenue Model

Company DescriptionIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

How the Company Makes MoneyIridex makes money by selling its laser systems and related consumable products to ophthalmologists, hospitals, and clinics globally. The company's revenue streams include the initial sale of laser systems and ongoing sales of consumable products, such as laser probes, which are used during procedures. Iridex also generates income through service and maintenance contracts for its equipment. Strategic partnerships with research institutions and key players in the medical device industry further enhance its market reach and contribute to its revenue growth.

Iridex Financial Statement Overview

Summary

Iridex is experiencing significant financial challenges with declining revenues, negative profit margins, and weakening balance sheet metrics. The ongoing negative cash flows and increasing leverage highlight liquidity and financial sustainability concerns. Strategic interventions are necessary to stabilize and improve financial health.

Income Statement

Neutral

Iridex has faced declining revenue over recent years, with a notable decrease from $56.97 million in 2022 to $48.67 million in 2024. The gross profit margin has also declined from 44.5% in 2022 to 40.1% in 2024, indicating eroding profitability. The company has consistently reported negative EBIT and EBITDA margins, reflecting ongoing operational challenges and unprofitability.

Balance Sheet

Negative

The balance sheet reflects a concerning financial position with stockholders' equity significantly declining from $23.3 million in 2022 to $2.1 million in 2024. The debt-to-equity ratio has increased substantially due to the lower equity base, posing potential financial risk. The equity ratio dropped from 35.4% in 2022 to 7.2% in 2024, indicating weakened financial stability.

Cash Flow

Negative

Iridex's cash flow situation is challenging, with negative operating cash flow and free cash flow observed over the recent years. Operating cash flow to net income ratio remains negative, implying inefficiencies in cash generation from operations. The free cash flow growth rate is negative, exacerbating liquidity concerns.

Dec 2024	Dec 2023	Dec 2022	Mar 2022	Mar 2021
Breakdown
Income Statement		Total Revenue
48.67M	51.87M	56.97M	53.90M	36.35M
	Gross Profit
19.50M	21.81M	25.37M	22.83M	15.56M
	EBIT
-8.30M	-10.01M	-7.54M	-7.53M	-6.58M
	EBITDA
-8.30M	-7.97M	-6.10M	-6.73M	-6.08M
	Net Income Common Stockholders
-8.91M	-9.57M	-7.55M	-5.22M	-6.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.39M	7.03M	13.92M	23.85M	11.63M
	Total Assets
29.14M	34.44M	42.29M	48.69M	27.97M
	Total Debt
1.91M	2.75M	1.77M	2.66M	4.19M
	Net Debt
-482.00K	-4.29M	-12.15M	-21.20M	-7.44M
	Total Liabilities
27.04M	24.91M	25.06M	25.39M	10.60M
	Stockholders Equity
2.10M	9.52M	17.23M	23.30M	17.37M
Cash Flow		Free Cash Flow
-7.29M	-6.85M	-9.80M	8.00M	-3.33M
	Operating Cash Flow
-7.29M	-6.75M	-9.52M	8.22M	-3.24M
	Investing Cash Flow
-13.00K	-109.00K	-286.00K	-5.56M	-93.00K
	Financing Cash Flow
2.60M	-5.00K	-73.00K	9.47M	2.47M

Iridex Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price1.22

Price Trends

50DMA

1.13

Positive

100DMA

1.41

Negative

200DMA

1.61

Negative

Market Momentum

MACD

0.02

Negative

RSI

62.01

Neutral

STOCH

81.62

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRIX, the sentiment is Neutral. The current price of 1.22 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 1.13, and below the 200-day MA of 1.61, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.01 is Neutral, neither overbought nor oversold. The STOCH value of 81.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IRIX.

Iridex Risk Analysis

Iridex disclosed 49 risk factors in its most recent earnings report. Iridex reported the most risks in the “Finance & Corporate” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Iridex Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
IRIX	48 Neutral	$20.48M	―	-153.37%	―	-6.17%	8.27%
LFWD	43 Neutral	$15.95M	―	-88.56%	―	85.24%	-27.93%
IINN	35 Underperform	$15.70M	―	-196.69%	―	―	―
AXDX	34 Underperform	$14.56M	―	110.26%	―	-2.99%	59.87%
BSGM	34 Underperform	$22.31M	―	5400.35%	―	122.22%	79.08%

* Healthcare Sector Average

Performance Comparison

IRIX

Iridex

1.22

-1.64

-57.34%

AXDX

Accelerate Diagnostics

0.58

-0.34

-36.96%

LFWD

Lifeward

1.50

-3.27

-68.55%

BSGM

BioSig Technologies

0.92

-0.42

-31.34%

ADGM

Adagio Medical Holdings

1.30

-10.05

-88.55%

IINN

Inspira Technologies Oxy BHN

0.61

-1.26

-67.38%

Iridex Earnings Call Summary

Earnings Call Date:Mar 27, 2025

(Q4-2024)

% Change Since: 38.64%|

Next Earnings Date:May 08, 2025

Earnings Call Sentiment Positive

The earnings call reflects a positive outlook for IRIDEX with significant achievements in cost reduction and strategic investment, leading to financial stabilization and revenue growth. However, challenges remain, particularly in the retina product segment and the overall net loss, though the financial performance has improved from the previous year.

Q4-2024 Updates

Positive Updates

Successful Cost Reduction Program

The company successfully implemented a cost-reduction program, completed in Q4 2024, which stabilized the business and positioned it for positive cash flow from operations.

Strategic Investment by Novel Innovations

IRIDEX received a strategic investment from Novel Innovations, strengthening the balance sheet with $10 million and an option for an additional $10 million. The investment was made at a significant premium, reflecting the strategic nature and potential value of IRIDEX.

Revenue Growth and Improved Financial Performance

IRIDEX reported year-over-year revenue growth in Q4 2024, with revenue increasing to $12.7 million, up from $12.5 million in the prior year. The gross margin improved to 44.0% from 39.2% in the previous year, and the company achieved positive adjusted EBITDA for the first time in recent history.

Increased Sales of Cyclo G6 Glaucoma Products

Sales of the Cyclo G6 glaucoma product family increased by 9%, with 13,300 probes sold compared to 12,700 in the prior year, and 47 laser systems sold compared to 35 in the same quarter of the prior year.

Negative Updates

Decrease in Retina Product Revenue

Retina product revenue decreased by 3% compared to the prior year period, primarily due to deferral of capital purchases leading to lower system sales internationally.

Net Loss Despite Improvements

The company reported a net loss of $0.8 million or $0.05 per share in Q4 2024, although this was an improvement from a net loss of $3.0 million or $0.18 per share in the prior year.

Company Guidance

During the fourth quarter of 2024, IRIDEX implemented several strategic initiatives aimed at enhancing business performance for 2025. A key focus was the successful completion of a cost-reduction program, which aligned expenses with revenue projections, contributing to a positive adjusted EBITDA of $0.4 million, a notable improvement from a negative $2.0 million in the prior year. Revenue for Q4 2024 increased to $12.7 million, up from $12.5 million in the same period of the previous year, with a gross profit of $5.6 million, reflecting a 44.0% gross margin. The Cyclo G6 glaucoma product line showed promising growth, generating $3.3 million in revenue and selling 13,300 probes, compared to 12,700 the previous year. Additionally, a strategic investment by Novel Innovations provided $10 million, with an option for an additional $10 million, strengthening the balance sheet and positioning IRIDEX for future growth. The company plans to pre-announce its Q1 2025 results to address a prolonged insider trading window closure and to highlight the perceived undervaluation of its stock, particularly in light of Novel's investment at a $2 per share valuation.

Iridex Corporate Events

Executive/Board ChangesPrivate Placements and FinancingBusiness Operations and Strategy

Iridex Secures Strategic Investment and Appoints New CFO

Positive

Mar 20, 2025

On March 19, 2025, Iridex Corporation announced the closing of a strategic investment with Novel Inspiration International Co., Ltd., resulting in $10 million in gross proceeds and an option for an additional $10 million for future growth initiatives. This transaction, which includes the sale of Series B Preferred Stock and convertible notes, aims to enhance Iridex’s ability to pursue opportunities in advanced laser-based treatments, particularly for glaucoma, following changes in reimbursement policies for certain surgical devices. Additionally, the company appointed Romeo Dizon as Chief Financial Officer, replacing Fuad Ahmad, as part of its strategic review process.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.